High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients.

Immune activation plays an important role in the progression of chronic heart failure (CHF). We sought to investigate whether different degrees of tumor necrosis factor-alpha (TNF-alpha) activation are associated with exercise intolerance, neurohormonal activation and alterations in muscle mass and function in patients with CHF without cardiac cachexia. Patients were divided into quartiles according to their TNF levels (first quartile: 0.98-4.90 pg/ml, second quartile: 5.00-6.60 pg/ml; third quartile 6.80-9.00 pg/ml; fourth quartile 9.80-32.00 pg/ml). Patients underwent cardiopulmonary exercise testing, quadriceps muscle strength test, quadriceps fatigue test, and assessment of thigh muscle and fat cross-sectional area (CSA) by computerized tomography scanning. Patients in the highest TNF quartile had the lowest peak oxygen consumption [13.1 (+/-4.1) ml/kg/min vs 18.1 (+/-5.3), 18.8 (+/-4.8) and 18.7 (+/-5.6) ml/kg/min, P<0.01] the greatest relation of ventilation and dioxide production (VE/VCO(2)) slope (P<0.05) and the most elevated catecholamine levels (P<0.05) compared to patients in the first three quartiles. Patients with the lowest TNF levels had preserved thigh muscle size and quadriceps strength. Strength/muscle CSA was similar in the four groups. Muscle strength during fatigue testing was significantly lower in the fourth quartile (P=0.01) compared with the other three groups. In CHF patients only the highest levels of TNF are associated with poor functional status and neurohormonal activation. This group of patients may represent the appropriate target population for TNF antagonism.

[1]  P. Robbins,et al.  Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. , 2000, Circulation.

[2]  D. Wagner,et al.  The role of tumor necrosis factor in the pathophysiology of heart failure. , 2000, Journal of the American College of Cardiology.

[3]  R. Ferrari,et al.  Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. , 1999, Circulation.

[4]  B. Bozkurt,et al.  Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.

[5]  B. Bozkurt,et al.  An overview of tumor necrosis factor α and the failing human heart , 1999 .

[6]  P. Ponikowski,et al.  Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. , 1999, European heart journal.

[7]  G. Schuler,et al.  Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. , 1999, Journal of the American College of Cardiology.

[8]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[9]  P. Poole‐Wilson,et al.  Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. , 1998, QJM : monthly journal of the Association of Physicians.

[10]  S. Anker,et al.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.

[11]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[12]  P. Ponikowski,et al.  Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. , 1997, Journal of the American College of Cardiology.

[13]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[14]  P. Poole‐Wilson,et al.  The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. , 1997, European heart journal.

[15]  D. Zechner,et al.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. , 1996, The Journal of clinical investigation.

[16]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[17]  M. Piepoli,et al.  Predictors of exercise capacity in chronic heart failure. , 1994, European heart journal.

[18]  M. Yoshizumi,et al.  Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. , 1993, Circulation research.

[19]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[20]  R. Lenkinski,et al.  Contribution of Skeletal Muscle Atrophy to Exercise Intolerance and Altered Muscle Metabolism in Heart Failure , 1992, Circulation.

[21]  J. McMurray,et al.  Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. , 1991, British heart journal.

[22]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[23]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[24]  D. Hossfeld,et al.  TNF-induced cardiomyopathy , 1990, The Lancet.

[25]  M. Singer,et al.  TUMOUR NECROSIS FACTOR IN BRONCHOPULMONARY SECRETIONS OF PATIENTS WITH ADULT RESPIRATORY DISTRESS SYNDROME , 1989, The Lancet.

[26]  J. Kovacs,et al.  The cardiovascular response of normal humans to the administration of endotoxin. , 1989, The New England journal of medicine.

[27]  K. Tracey,et al.  Peptide Regulatory Factors CACHECTIN/TUMOUR NECROSIS FACTOR , 1989, The Lancet.

[28]  K. Tracey,et al.  Cachectin/tumour necrosis factor. , 1989, Lancet.

[29]  J. Gabrilove,et al.  The acute metabolic effects of tumor necrosis factor administration in humans. , 1987, Archives of surgery.

[30]  R. H. T. Edwards,et al.  Size and composition of the calf and quadriceps muscles in Duchenne muscular dystrophy A tomographic and histochemical study , 1983, Journal of the Neurological Sciences.

[31]  M. Morrell,et al.  ABSORPTION OF PENTAGASTRIN FROM GASTROINTESTINAL TRACT IN MAN , 1975, The Lancet.

[32]  V. Schuermans,et al.  IMPAIRED NEUTROPHIL PHAGOCYTOSIS , 1974 .